Association of dipeptidyl peptidase-4 inhibitor use and the risk of asthma development among type 2 diabetes patients.
Peng-Fei LiChi-Hsiang ChungJhih-Syuan LiuChieh-Hua LuSheng-Chiang SuFeng-Chih KuoLi-Ju HoKuan-Chan ChenYu-Te SuNain-Feng ChuChien-Hsing LeeChang-Hsun HsiehYi-Jen HungFu-Huang LinWu-Chien ChienYao-Jen LiangPublished in: Therapeutic advances in respiratory disease (2022)
The use of DPP-4i decreased the risk and severity of asthma with a class effect among No-AE, AE, status of asthma events, but not in ET-tube intubated events. Our report suggests that DPP-4i may play a role in attenuating the impact of asthma on incidence in the future and on more severe forms of disease exacerbation in T2DM patients.
Keyphrases
- chronic obstructive pulmonary disease
- end stage renal disease
- type diabetes
- lung function
- ejection fraction
- newly diagnosed
- chronic kidney disease
- prognostic factors
- allergic rhinitis
- peritoneal dialysis
- cardiovascular disease
- metabolic syndrome
- patient reported outcomes
- cystic fibrosis
- risk factors
- adipose tissue
- air pollution
- skeletal muscle
- glycemic control
- mechanical ventilation